Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Hanna
Nasser
N
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D000068437:Pemetrexed; D010671:Phenylurea Compounds; D010880:Piperidines / Q000008:administration & dosage; D011336:Probability; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000077157:Sorafenib; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D005971:Glutamates; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D011799:Quinazolines; D043823:Taxoids; D000068437:Pemetrexed; D000077143:Docetaxel; D009536:Niacinamide; D000068258:Bevacizumab; D006147:Guanine; D000077157:Sorafenib; C452423:vandetanib